Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia

NCT03937544 is registered in ClinicalTrials.gov with National University of Malaysia as lead sponsor.

NCT NCT03937544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03937544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia
Lead sponsor
National University of Malaysia
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 19, 2019
Completion date
March 18, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b acute lymphoblastic leukaemia, relapsed b acute lymphoblastic leukaemia